IPERION (IPR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
30 Sep, 2026Opening remarks and agenda
Meeting held virtually with voting by poll and proxy forms accepted until 4:00 P.M.
Apologies noted from two directors; only one present to lead the meeting.
Meeting included welcome, introductions, formalities, a shareholder presentation, Q&A, and resolutions.
Financial performance review
No interest income in 2026 as cash was kept liquid for anticipated sales orders.
Outsourced manufacturing fee fully discounted for 2026 and will remain so through March 2028.
Admin expenses stable or decreased, with savings in travel and audit fees but higher stock exchange costs.
Net loss for the year was $294,595, with net assets at $53,803 and cash/term deposits at $155,492 as of March 2026.
No impairment expenses for 2026; trademark registration costs completed.
Board and executive committee updates
Directors and management are deferring 50% of their fees, and 33% of management fees, to conserve cash since January 2026.
No changes in the number of shares on issue.
Latest events from IPERION
- Net loss improved 35% year-over-year, driven by cost savings and deferred director fees.IPR
H2 2026 - Pathoglaze® achieved global certifications and broad trials as financials reflected higher costs.IPR
Investor presentation - Resolutions passed, financials tightened, and Pathoglaze advanced toward commercial rollout.IPR
Investor presentation - Net loss narrowed to $158,254 with no revenue and net tangible assets per share halved.IPR
H1 2026 - Net loss halved, costs reduced, and focus shifts to securing sales from product trials.IPR
H2 2025 - Net loss narrowed with no revenue, lower costs, and no dividend declared for the half year.IPR
H1 2025